Edition:
United States

Rexahn Pharmaceuticals Inc (RNN.A)

RNN.A on American Stock Exchange

0.16USD
9 Dec 2016
Change (% chg)

$0.00 (+0.81%)
Prev Close
$0.16
Open
$0.16
Day's High
$0.17
Day's Low
$0.15
Volume
113,152
Avg. Vol
102,982
52-wk High
$0.45
52-wk Low
$0.14

RNN.A

Chart for RNN.A

About

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein... (more)

Overall

Beta: -0.02
Market Cap(Mil.): $38.36
Shares Outstanding(Mil.): 237.37
Dividend: --
Yield (%): --

Financials

  RNN.A Industry Sector
P/E (TTM): -- 40.79 30.36
EPS (TTM): -0.06 -- --
ROI: -57.04 -0.56 15.27
ROE: -66.58 -1.20 16.60

BRIEF-Rexahn Pharmaceuticals reports Q3 loss per share of $0.01

* Rexahn Pharma - expects cash, investments as of Sept 30, 2016 to be sufficient to fund cash flow requirements for activities into first half of 2018

Nov 07 2016

BRIEF-Rexahn Pharmaceuticals says received notice of allowance from U.S PTO

* Received notice of allowance from U.S PTO for a patent for claims related to synthesis of its novel anti-cancer investigational drug candidate, rx-3117 Source text for Eikon: Further company coverage:

Oct 31 2016

BRIEF-Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117, Supinoxin phase I trial

* Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117 in metastatic pancreatic cancer and supinoxin phase I trial at 2016 European Society For Medical Oncology (ESMO) congress

Oct 10 2016

BRIEF-Rexahn Pharmaceuticals announces $6 million registered direct offering

* Rexahn Pharmaceuticals -Rexahn announces $6 million registered direct offering Source text:

Sep 14 2016

BRIEF-Rexahn Pharmaceuticals Q2 loss per share $0.01

* Rexahn Pharmaceuticals reports second quarter 2016 financial and operational results

Aug 08 2016

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,478.00p +18.00
Merck & Co., Inc. (MRK.N) $61.23 +1.11

Earnings vs. Estimates